8-K filed Aug 14, 2026 at 08:36 ET
Outlook Therapeutics priced a $55.0M registered direct offering of 55,555,556 shares of common stock and accompanying warrants to purchase up to 55,555,556 shares, at a combined price of $0.99 per unit. The underwriters also exercised their option to purchase additional warrants covering 8,333,333 shares. The offering is heavily dilutive (~33% of current market cap in base shares alone) and the warrants, exercisable at $1.10 for 5 years, create additional overhang. The company's largest stockholder, CEO, and CFO participated, signaling some insider confidence, but the dilutive structure and low offering price relative to the $166M market cap are clearly negative for existing holders.